Mol Biol Evol:遗传负荷的积累对肿瘤细胞生长产生重要影响

2019-02-11 佚名 北京基因组研究所

近期,中国科学院北京基因组研究所吕雪梅研究组和台湾大学临床医学研究所王弘毅研究组联合在Molecular Biology and Evolution 发表题为Genetic load and potential mutational meltdown in cancer cell populations 的研究论文,该研究揭示,肿瘤生长中会积累大量对肿瘤细胞有害的突变,而肿瘤群体大小、有害突变速率

近期,中国科学院北京基因组研究所吕雪梅研究组和台湾大学临床医学研究所王弘毅研究组联合在Molecular Biology and Evolution 发表题为Genetic load and potential mutational meltdown in cancer cell populations 的研究论文,该研究揭示,肿瘤生长中会积累大量对肿瘤细胞有害的突变,而肿瘤群体大小、有害突变速率(mutation rate)和突变效应(mutational effect)决定了肿瘤群体存亡的命运。

研究人员从宫颈癌HeLa细胞系中选取单细胞进行克隆培养,通过多个单细胞克隆培养发现,细胞已经发生染色体倍型和生长速率异质性;大部分细胞系相对于祖先细胞生长速率有了明显下降。通过全基因组测序,生长速率较慢的细胞系拷贝数变异(copy number variation)数量显着多于生长速率较快的细胞系。通过对染色体核型的分析,发现生长速率较慢的细胞染色体数量显着升高。随后研究人员计算了有害突变的突变率,得到HeLa细胞系单次分裂平均产生0.29个有害突变,每增加一个有害突变会使肿瘤细胞的生长速率下降18%,得出平均每一代群体的适应度下降~5%(0.29×0.18),远高于此前在其它物种中的估计,验证了肿瘤生长会承受很高的遗传负荷(genetic load)。最后,为了回答肿瘤群体如何避免被消亡(mutational meltdown)的问题,研究人员利用已估计的参数模拟肿瘤从单细胞开始生长的过程,通过多次模拟,仅有不到10%克隆存活,即使在存活的群体中,大部分细胞的适合度(fitness)相比他们祖先细胞有明显降低。但群体中没有携带任何有害突变(mutation free)的细胞数量也一直增加,而这些细胞可以使肿瘤群体免于消亡的危险。

该研究揭示肿瘤细胞内部的演化方向由驱动突变(driver mutation)和“乘客”突变(passenger mutation)相互平衡共同决定。虽然肿瘤细胞呈现中性演化的特征,但演化过程仍然受到选择。过往研究主要集中在少部分驱动突变,却忽视了大量“乘客”突变在肿瘤生长中的负驱动作用。肿瘤演化的高突变率和中性特征,导致肿瘤细胞的群体拥有极大异质性,也是耐药复发的主要原因,给传统的肿瘤治疗带来很大困难。研究提示针对性抑制“乘客”突变少而适应度高的克隆进行治疗,有助于提升肿瘤临床治疗效果。该研究得到中科院战略性先导科技专项、国家自然科学基金“微进化过程的多基因相互作用”、中科院重点部署项目等的资助。

原始出处:

Yuezheng Zhang,et al.Genetic Load and Potential Mutational Meltdown in Cancer Cell Populations.Mol Biol Evol.15 December 2019

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918529, encodeId=ea36191852952, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jul 03 11:15:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767610, encodeId=56b41e67610ec, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jul 15 19:15:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313029, encodeId=2fa61313029c9, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Feb 13 13:15:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569032, encodeId=378615690325d, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Wed Feb 13 13:15:00 CST 2019, time=2019-02-13, status=1, ipAttribution=)]
    2019-07-03 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918529, encodeId=ea36191852952, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jul 03 11:15:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767610, encodeId=56b41e67610ec, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jul 15 19:15:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313029, encodeId=2fa61313029c9, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Feb 13 13:15:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569032, encodeId=378615690325d, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Wed Feb 13 13:15:00 CST 2019, time=2019-02-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918529, encodeId=ea36191852952, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jul 03 11:15:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767610, encodeId=56b41e67610ec, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jul 15 19:15:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313029, encodeId=2fa61313029c9, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Feb 13 13:15:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569032, encodeId=378615690325d, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Wed Feb 13 13:15:00 CST 2019, time=2019-02-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918529, encodeId=ea36191852952, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jul 03 11:15:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767610, encodeId=56b41e67610ec, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jul 15 19:15:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313029, encodeId=2fa61313029c9, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Feb 13 13:15:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569032, encodeId=378615690325d, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Wed Feb 13 13:15:00 CST 2019, time=2019-02-13, status=1, ipAttribution=)]

相关资讯

Lancet oncol:Tisotumab vedotin可安全治疗多种固体肿瘤

Tisotumab vedotin是一种针对在多种实体肿瘤中均有表达、与临床预后差相关的组织因子的首个人体内的抗体-药物偶联物。现研究人员在表达组织因子的局部晚期或转移性固体肿瘤患者的混合人群中评估tisotumab vedotin的安全性、耐受性、药代动力学和抗肿瘤活性。研究人员在USA和欧洲的21个中心开展一个I-II期的开放性、剂量递增性和剂量扩展性研究(InovaTV201),招募年满18

开年大吉:张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变:肿瘤学I期临床试验年度报告》

长期以来,冗长的药品审评流程导致很多新药在中国大陆迟迟无法上市,患者面临无药可用的困境,这一现象在业内被称为“药滞(Drug-lag)”。2017年以来,国家实施了一系列药品审评、监管制度改革,旨在彻底扭转这一困局。近年来,抗肿瘤药物研发模式也发生了巨大变革,“无缝(seamless)设计”逐渐取代传统的三阶段药物开发模式。I期临床试验从原来的安全性试验转变为机制验证性(proof-of-mech

Cell:细菌会促进肺部肿瘤生长

近日,美国麻省理工学院(MIT)的癌症生物学家发现在肺癌中被肿瘤用于促进自身生存的一种新机制:它们会改变肺内菌群,刺激免疫系统产生炎症环境,进而帮助肿瘤细胞繁殖。

NATURE:中性粒细胞可护送循环肿瘤细胞

研究人员认为,更好地理解和定义癌细胞和免疫细胞之间相互作用的特征对于新癌症疗法的开发是至关重要的。

SCIENCE:肿瘤转移至淋巴结需要YAP依赖性代谢适应

在癌症患者中,肿瘤向前哨淋巴结(LN)的转移预测着疾病的进展,并且经常指导治疗决策。